Antibe Therapeutics, Inc. Stock Price - ATBPF

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Small Cap Pro
Monthly Subscription
for only
$49.05
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN
Antibe Therapeutics, Inc. ATBPF Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.0008 0.35% 0.2308 0.242 0.23 0.242 0.23 16:59:53
Bid Price Ask Price Spread Spread % News
0.226 0.2417 0.0157 6.50% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
12 17,880 $ 0.235852 $ 4,217 120,670 0.1773 - 0.427
Last Trade Time Type Quantity Stock Price Currency
15:55:24 1,000 $ 0.2308 USD

Antibe Therapeutics, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 50.8M 220.11M $ -7.43M - -6.84 187.18M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Antibe Therapeutics, Inc. News

Latest ATBPF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATBPF Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.240.2440.2240.231112k490k149k-0.0092-3.83%
1 Month0.262950.273640.2240.24115k569k140k-0.03215-12.23%
3 Months0.20180.273640.19750.24021000569k120k0.02914.37%
6 Months0.1840.273640.180.22862531M118k0.046825.43%
1 Year0.31170.4270.17730.23162531M86k-0.0809-25.95%
3 Years0.09510.59930.06090.23841001M79k0.1357142.69%
5 Years0.4770.59930.060.2380501M75k-0.2462-51.61%

Antibe Therapeutics, Inc. Description

Antibe is a commercial-stage pharmaceutical company focused on pain, inflammation and regenerative medicine. Antibe's lead drug, ATB-346, targets the global need for a safer non-steroidal anti-inflammatory drug ('NSAID') for treating chronic pain and inflammation with non-addictive medication. Antibe's subsidiary, Citagenix Inc. ('Citagenix'), is a leader in Canada in the sales and marketing of tissue regenerative products servicing the dental and orthopaedic marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience in the Canadian medical device industry. Citagenix has grown a comprehensive portfolio of high-quality, branded biologics and medical devices that promote bone regeneration. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.